Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
23 Noviembre 2022 - 10:35AM
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)
(Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on
developing novel drugs for the targeted treatment of
neuropsychiatric disorders, epilepsy, and pain, today announced
that Mark A. Smith M.D., Ph.D. will join the Company as Chief
Medical Officer, effective December 1, 2022. The Company also
announces that Dr. Revati Shreeniwas’ engagement with Bright Minds
as Chief Medical Officer has been terminated.
“I’m thrilled to welcome Dr. Smith to the Bright
Minds team. A seasoned executive in CNS drug development, Dr. Smith
has directed over 50 clinical trials across all stages of
development. Dr Smith's extensive background in psychiatry will
strengthen the clinical implementation of our next generation
5-HT2A agonists. His depth and breadth of knowledge in
neuropsychiatry, development, translational neuroscience, and
clinical trial design will be a great asset as we continue to
advance our pipeline of novel compounds through clinical trials,”
said Ian McDonald, CEO and Co-founder of Bright Minds
Biosciences.
“It’s an exciting time to join Bright Minds with
the Phase I trial for its lead program, BMB-101, currently
underway. Proposed to treat Dravet syndrome, an epilepsy syndrome
that begins in infancy or early childhood, BMB-101 is a promising
drug candidate with the potential to change lives. My background is
uniquely well-suited to the opportunity, and I look forward to
seeing BMB-101 and the rest of the pipeline through their
development stages,” stated Dr. Smith.
Prior to joining Bright Minds, Dr. Smith was
Chief Medical Officer at VistaGen Therapeutics, where he led the
clinical development of drug candidates in the areas of major
depression, social anxiety disorder, and depression through all
phases of development. Previously, Dr. Smith served as the Clinical
Lead for Neuropsychiatry at Teva Pharmaceuticals, where he was
accountable for the strategy and clinical development of
neuropsychiatric drugs with a focus on schizophrenia, sleep
disorders, and agitation. He also held a range of director
positions, including as Executive Director of Clinical Development
at AstraZeneca Pharmaceutical Company, where he led the development
of several novel chemical entities targeting treatment-resistant
depression, anxiety, and schizophrenia.
Dr. Smith was also Senior Director of
Experimental Medicine of Global Clinical Development and Innovation
at Shire Pharmaceuticals and Senior Investigator and Principal
Research Scientist of CNS Diseases at DuPont Pharmaceuticals. Prior
to joining the pharmaceutical industry, he served as a Senior Staff
Scientist of the Biological Psychiatry Branch and Senior Staff
Fellow of the Clinical Neuroendocrinology Branch at the U.S.
National Institute of Mental Health (NIMH).
Dr. Smith received his Bachelor's degree and
Master of Science from Yale University, his Doctor of Medicine and
Doctor of Philosophy in Physiology and Pharmacology from the
University of California, San Diego, and completed his residency in
the Department of Psychiatry at Duke University Medical Center. He
currently serves on the National Institute of Mental Health
Translational Neuropsychopharmacology Task Force.
About Bright Minds
Bright Minds is focused on developing novel
transformative treatments for neuropsychiatric disorders, epilepsy,
and pain. Bright Minds has a portfolio of next-generation serotonin
agonists designed to target neurocircuit abnormalities that are
responsible for difficult to treat disorders such as resistant
epilepsy, treatment resistant depression, PTSD, and pain. The
Company leverages its world-class scientific and drug development
expertise to bring forward the next generation of safe and
efficacious drugs. Bright Minds’ drugs have been designed to
potentially retain the powerful therapeutic aspects of psychedelic
and other serotonergic compounds, while minimizing the side
effects, thereby creating superior drugs to first-generation
compounds, such as psilocybin.
Investor Contacts:Lisa WilsonE:
lwilson@insitecony.comT: 917-543-9932
Ian McDonaldCEO and DirectorE: ian@brightmindsbio.comT: 647 407
2515
This news release contains “forward-looking
information” which may include, but is not limited to, statements
with respect to expectations about the intended date Dr. Smith
becomes CMO, his work in respect of the Company’s development
pipeline and the proposed use of BMB-101 to treat Dravet Syndrome.
Often, but not always, forward-looking statements can be identified
by the use of words such as “plans”, “expects”, “is expected”,
“budget”, “scheduled”, “estimates”, “forecasts”, “intends”,
“anticipates”, or “believes” or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results “may”, “could”, “would”, “might” or
“will” be taken, occur or be achieved. A variety of factors,
including known and unknown risks, many of which are beyond our
control, could cause actual results to differ materially from the
forward-looking information in this press release. Additional risk
factors can also be found in the Company’s public filings under the
Company’s SEDAR profile at www.sedar.com. Forward-looking
statements contained herein are made as of the date of this press
release and the Company disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or results or otherwise. There can be no assurance
that forward-looking statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. The Company undertakes no
obligation to update forward-looking statements if circumstances,
management’s estimates or opinions should change, except as
required by securities legislation. Accordingly, the reader is
cautioned not to place undue reliance on forward-looking
statements.
Neither the Canadian Securities Exchange nor its
Regulation Services Provider accepts responsibility for the
adequacy or accuracy of this release.
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024